Chimerix, Inc. (CMRX)'s Brincidofovir (CMX001) Data Accepted For Three Presentations At 27th International Conference On Antiviral Research
5/6/2014 9:50:23 AM
DURHAM, N.C., May 6, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced three presentations on its investigational broad-spectrum antiviral brincidofovir (BCV, CMX001) at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.
Help employers find you! Check out all the jobs and post your resume.
comments powered by